Taysha Gene Therapies, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 95.16. In total, the insiders bought 31 364 118 and sold 943 112 TSHA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
95.16
Buy 31 364 118 Shares
Sell 943 112 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 27, 2024 Common Stock Buy Manning Paul B 1 333 333
May 29, 2024 Common Stock Buy Stalfort John A Iii 49 220
May 29, 2024 Stock Option (right to buy) Buy Stalfort John A Iii 98 440
May 29, 2024 Stock Option (right to buy) Buy Long Alison S 98 440
May 29, 2024 Common Stock Buy Long Alison S 49 220
May 29, 2024 Common Stock Buy Donenberg Phillip B. 49 220
May 29, 2024 Stock Option (right to buy) Buy Donenberg Phillip B. 98 440
May 29, 2024 Stock Option (right to buy) Buy Sepp-lorenzino Laura 98 440
May 29, 2024 Common Stock Buy Sepp-lorenzino Laura 49 220
Feb 02, 2024 Common Stock Sell Alam Kamran 1 288
Jan 02, 2024 Common Stock Buy Alam Kamran 590 413
Jan 02, 2024 Employee Stock Option (right to buy) Buy Alam Kamran 590 413
Jan 02, 2024 Common Stock Buy Nagendran Sukumar 863 617
Jan 02, 2024 Employee Stock Option (right to buy) Buy Nagendran Sukumar 863 617
Jan 02, 2024 Common Stock Buy Nolan Sean P. 1 184 688
Jan 02, 2024 Employee Stock Option (right to buy) Buy Nolan Sean P. 1 184 688
Dec 14, 2023 Employee Stock Option (right to buy) Buy Alam Kamran 187 582
Dec 14, 2023 Employee Stock Option (right to buy) Buy Nagendran Sukumar 334 005
Dec 14, 2023 Employee Stock Option (right to buy) Buy Nolan Sean P. 466 550
Nov 17, 2023 Common Stock Buy Manning Paul B 100 000
Nov 01, 2023 Stock Option (right to buy) Buy Long Alison S 43 800
Nov 01, 2023 Buy Long Alison S 0
Aug 24, 2023 Common Stock Sell Alam Kamran 33 000
Aug 16, 2023 Common Stock Buy Manning Paul B 16 466 667
Aug 16, 2023 Common Stock Buy Stalfort John A Iii 50 000
Click to get the best stock tips daily for free!

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies. Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ... TSHA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT